 "Biocon up 5% as USFDA issues CRL for proposed Biosimilar")
Biocon moved higher by over 5% to Rs 363 on BSE in noon deals after the company said the US Food and Drug Administration (USFDA) has issued a Complete Response Letter (CRL) for proposed Biosimilar Pegfilgrastim.
“The US Food and Drug Administration have issued a Complete Response Letter (CRL) for Mylan's Biologics License Application (BLA) for MYL-1401H, a proposed biosimilar pegfilgrastim. This product is a part of the biosimilars portfolio being developed jointly by Biocon and Mylan,” Biocon said in a BSE filing.
The CRL relates to the pending update of the BLA with certain CMC data from facility requalification activities post recent plant modifications. The CRL did not raise any questions on biosimilarity, pharmacokinetic/pharmacodynamic data, clinical data or immunogenicity, it added.
The company said it does not expect the CRL to impact the commercial launch timing of biosimilar pegfilgrastim in the US.
“We are committed to working with the agency to resolve the issues stated in the CRL expeditiously”, it added.
At 02:12 PM; the stock was up 5% at Rs 362 on the BSE, as compared to 0.23% rise in the S&P BSE Sensex. The trading volumes on the counter jumped nearly five-fold with a combined 5.4 million shares changed hands on the BSE and NSE.
“The US Food and Drug Administration have issued a Complete Response Letter (CRL) for Mylan's Biologics License Application (BLA) for MYL-1401H, a proposed biosimilar pegfilgrastim. This product is a part of the biosimilars portfolio being developed jointly by Biocon and Mylan,” Biocon said in a BSE filing.
The CRL relates to the pending update of the BLA with certain CMC data from facility requalification activities post recent plant modifications. The CRL did not raise any questions on biosimilarity, pharmacokinetic/pharmacodynamic data, clinical data or immunogenicity, it added.
The company said it does not expect the CRL to impact the commercial launch timing of biosimilar pegfilgrastim in the US.
“We are committed to working with the agency to resolve the issues stated in the CRL expeditiously”, it added.
At 02:12 PM; the stock was up 5% at Rs 362 on the BSE, as compared to 0.23% rise in the S&P BSE Sensex. The trading volumes on the counter jumped nearly five-fold with a combined 5.4 million shares changed hands on the BSE and NSE.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%